A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers

Anticancer Research

Volumn 17, Issue 5 B, 1997, Pages 3867-3871

  Yeh, Kun Huei ^a,b   Cheng, Ann Lii ^a,b   Lin, Ming Tseh ^a,b   Hong, Ruey Long ^a,b   Hsu, Chih Hung ^a,b   Lin, Jing Fang ^b   Chang, King Jeng ^a   Lee, Po Huang ^a   Chen, Yao Chang ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Colorectal cancers; High dose 5 fluorouracil; Leucovorin

Indexed keywords

FLUOROURACIL; FOLINIC ACID;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CATHETER; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIARRHEA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; METASTASIS; NAUSEA; OUTPATIENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; SURVIVAL TIME; VOMITING;

ADULT; AGED; ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; COLONIC NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECTAL NEOPLASMS; TREATMENT OUTCOME;

EID: 0031438467     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Heidelberger C, Chaudhuari NK, Danneberg P, Mooreh D, Griesbach L, Duschinsky R, et al: Fluorinated pyrimidine, a new class of tumor-inhibitory compounds. Nature 179: 663-666, 1957.
2. Grem JL: 5-Fluoropyrimidines. In: Cancer Chemotherapy and Biotherapy: Principles and Practice (Chabner BA and Longo DL, eds). Philadelphia, Lippincott-Raven Publishers, 1996, pp 149-212.
3. Grem JL, Hoth DF, Hamilton JM, King SA, Leyland-Jones B: Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid. Cancer Treat Rep 71: 1249-1264, 1987.
4. Erlichman C, Fine S, Wong A, Elhakim T: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 469-475, 1988.
5. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, et al: Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 7: 1407-1417, 1989.
6. Petrelli N, Douglass HO, Herrera L, Russell D, Stablein DM, Bruckner HW, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 7: 1419-1426, 1989.
7. Doroshow JH, Multhauf P, Leong L, Margolin K, Litchfield T, Akman S, et al: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8: 491-501, 1990.
8. Bruckner HW, Motwani BT: Chemotherapy of advanced cancer of the colon and rectum. Semin Oncol 18: 443-461, 1991.
9. Advanced Colorectal Cancer Meta-analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 10: 896-903, 1992.
10. Ardalan B, Chua L, Tian E, Reddy R, Sridhar K, Benedetto P, et al: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9: 625-30, 1991.
11. Ardalan B, Flores MR: A new complication of chemotherapy administered via permanent indwelling central venous catheter. Cancer 75: 2165-2168, 1991.
12. Yeh KH, Cheng AL: An alternative method to overcome central venous portable external infusion pump blockage in patients receiving weekly 24-hour high-dose fluorouracil and leucovorin. J Clin Oncol 12: 875-876, 1994 (letter).
13. Altman DG, Stavola BD, Love SB, Stepniewska KA: Review of survival analyses published in cancer journals. Br J Cancer 72: 511-518, 1995.
14. Oken MM, Creech RH, Tormey DC, Horton J: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.
15. Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481, 1958.
16. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352-358, 1990.
17. The Gastrointestinal Tumor Study Group: Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. J Clin Oncol 10: 549-557, 1992.
18. Poon MA, O'Connel MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, et al: Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9: 1967-1972, 1991.
19. Houghton JA, Williams LG, deGraaf SSN, Cheshire PJ, Rodman JH, Maneval DC, et al: Relationship between dose rate of [6RS] leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylene-tetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts. Cancer Res 50: 3493-3502, 1990.
20. Ardalan B, Singh G, Silberman H: A randomized phase I-II study of short-term infusion of high-dose 5-fluorouracil with or without N-(phosphonacetyl) L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 6: 1053-1058, 1988.
21. Harris BE, Song R, Soong SJ, Diasio RB: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197-201, 1990.
22. Fleming RA, Milano G, Thyss A, Etienne MC, Renee N, Schneider M, et al: Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52: 2899-2902, 1992.
23. Fraile RJ, Baker LH, Buroker TR, Horwitz J, Vaitkevicius VK: Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 40: 2223-2228, 1980.
24. Meyers CE, Young RC, Chabner BA: Biochemical determinants of 5-fluorouracil response in vivo: the role of deoxyuridylate pool expansion. J Clin Invest 56: 1231-1238, 1975.
25. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, et al: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J Clin Oncol 13: 1303-1311, 1995.
26. Aranda E, Cervantes A, Dorta J, Blanco E, Fernandez-Martos C, Cruz-Hernandez JJ. et al: A phase II trial of weekly high dose continuous infusion of 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. Cancer 76: 559-563, 1995.
27. Becouarn YH, Brunet RC, Rouhier MP, Bussieres EJ, Avril AR, Richaud PM, et al: High dose folinic acid and 5-fluorouracil bolus and continuous infusion for patients with advanced colorectal cancer Cancer 76: 1126-1131, 1995.